Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study

被引:38
作者
Almagro, Pere [1 ]
Martinez-Camblor, Pablo [2 ]
Soriano, Joan B. [3 ]
Marin, Jose M. [4 ]
Alfageme, Inmaculada [5 ,6 ]
Casanova, Ciro
Esteban, Cristobal [7 ]
Soler-Cataluna, Juan J. [8 ]
De-Torres, Juan P. [9 ]
Celli, Bartolome R. [10 ]
Miravitlles, Marc [11 ]
机构
[1] Hosp Univ Mutua Terrassa, Dept Internal Med, Acute Geriatr Care Unit, Barcelona, Spain
[2] Asturias Biomed Res Off, Oviedo, Spain
[3] Hosp Univ Son Espases, Fdn Invest Saniat Illes Balers, Balearic Islands, Spain
[4] Hosp Univ Miguel Servet, Resp Dept, Zaragoza, Spain
[5] Valme Univ Hosp, Resp Dept, Seville, Spain
[6] Hosp Nuestra Senora Candelaria, Resp Dept, Tenerife, Spain
[7] Hosp Galdakao Usansolo, Resp Dept, Bizkaia, Spain
[8] Hosp Arnau Vilanova, Resp Dept, Valencia, Spain
[9] Cli nica Univ Navarra, Resp Dept, Pamplona, Spain
[10] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
[11] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain
来源
PLOS ONE | 2014年 / 9卷 / 02期
关键词
OBSTRUCTIVE PULMONARY-DISEASE; BODE INDEX; MORTALITY; RISK; CLASSIFICATION; EXACERBATIONS; COMORBIDITY; DISABILITY; SEVERITY; OUTCOMES;
D O I
10.1371/journal.pone.0089866
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: FEV1 is universally used as a measure of severity in COPD. Current thresholds are based on expert opinion and not on evidence. Objectives: We aimed to identify the best FEV1 (% predicted) and dyspnea (mMRC) thresholds to predict 5-yr survival in COPD patients. Design and Methods: We conducted a patient-based pooled analysis of eleven COPD Spanish cohorts (COCOMICS). Survival analysis, ROC curves, and C-statistics were used to identify and compare the best FEV1 (%) and mMRC scale thresholds that predict 5-yr survival. Results: A total of 3,633 patients (93% men), totaling 15,878 person-yrs. were included, with a mean age 66.469.7, and predicted FEV1 of 53.8% (+/- 19.4%). Overall 975 (28.1%) patients died at 5 years. The best thresholds that spirometrically split the COPD population were: mild >= 70%, moderate 56-69%, severe 36-55%, and very severe <= 35%. Survival at 5 years was 0.89 for patients with FEV1 >= 70 vs. 0.46 in patients with FEV1 <= 35% (H. R: 6; 95% C. I.: 4.69-7.74). The new classification predicts mortality significantly better than dyspnea (mMRC) or FEV1 GOLD and BODE cutoffs (all p<0.001). Prognostic reliability is maintained at 1, 3, 5, and 10 years. In younger patients, survival was similar for FEV1 (%) values between 70% and 100%, whereas in the elderly the relationship between FEV1 (%) and mortality was inversely linear. Conclusions: The best thresholds for 5-yr survival were obtained stratifying FEV1 (%) by >= 70%, 56-69%, 36-55%, and <= 35%. These cutoffs significantly better predict mortality than mMRC or FEV1 (%) GOLD and BODE cutoffs.
引用
收藏
页数:7
相关论文
共 42 条
  • [41] Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
    Cortellini, Alessio
    Brunetti, Leonardo
    Di Fazio, Giuseppina Rita
    Garbo, Edoardo
    Pinato, David J.
    Naidoo, Jarushka
    Katz, Artur
    Loza, Monica
    Neal, Joel W.
    Genova, Carlo
    Gettinger, Scott
    Kim, So Yeon
    Jayakrishnan, Ritujith
    El Zarif, Talal
    Russano, Marco
    Pecci, Federica
    Di Federico, Alessandro
    Awad, Mark
    Alessi, Joao, V
    Montrone, Michele
    Owen, Dwight Hall
    Signorelli, Diego
    Fidler, Mary Jo
    Li, Mingjia
    Camerini, Andrea
    De Giglio, Andrea
    Young, Lauren
    Vincenzi, Bruno
    Metro, Giulio
    Passiglia, Francesco
    Yendamuri, Sai
    Guida, Annalisa
    Ghidini, Michele
    Awosika, Nichola O.
    Napolitano, Andrea
    Fulgenzi, Claudia A. M.
    Grisanti, Salvatore
    Grossi, Francesco
    D'Incecco, Armida
    Josephides, Eleni
    Van Hemelrijck, Mieke
    Russo, Alessandro
    Gelibter, Alain
    Spinelli, Gianpaolo
    Verrico, Monica
    Tomasik, Bartlomiej
    Giusti, Raffaele
    Newsom-Davis, Thomas
    Bria, Emilio
    Sebastian, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [42] Adherence to guideline-recommended HbA1c testing frequency and better outcomes in patients with type 2 diabetes: a 5-year retrospective cohort study in Australian general practice
    Imai, Chisato
    Li, Ling
    Hardie, Rae-Anne
    Georgiou, Andrew
    BMJ QUALITY & SAFETY, 2021, 30 (09) : 706 - 714